https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-04-17 10:13:542023-04-17 10:20:09US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
https://www.aigom.it/wp-content/uploads/2022/12/logo-sito.png00Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-04-07 12:57:032023-04-07 12:59:21Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial.
https://www.aigom.it/wp-content/uploads/2023/01/31-MARZO-ULTIMISSIMO-MARZO.jpg903642Alessia Losihttps://www.aigom.it/wp-content/uploads/2022/12/logo-sito.pngAlessia Losi2023-04-03 14:22:262023-04-07 07:44:31RASSEGNA STAMPA 31 MARZO 2023 | FOLLOW UP OF EARLY BREAST CANCER: WORKING FOR A 2023 CONSENSUS
